Author

A. Brodbelt

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 2 Research Focus:differential expression· 2 Organism:human· 2 Approach:statistical model· 2 Research Focus:cell type annotation· 1 Research Focus:chromatin & epigenetic regulation· 1 Assay:DNA methylation· 1 Research Focus:drug response / drug discovery· 1

Frequent Co-Authors

A. Bruning-Richardson· 2 shared A. Chakrabarty· 2 shared A. Droop· 2 shared A. Ismail· 2 shared G. Tanner· 2 shared L. F. Stead· 2 shared N. Rippaus· 2 shared A. F-Bruns· 1 shared

Activity by Year

2019-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 43 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

A. Bruning-Richardson

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

IDHwt glioblastomas can be stratified by their transcriptional response to standard treatment, with implications for targeted therapy

G. Tanner, R. Barrow, M. Finetti, S. Ajaib, N. Ahmed, S. Pollock, N. Rippaus, A. F. Bruns, K. Syed, J. Poulter, E. A. Wilson, C. A. Johnson, F. S. Varn, A. Bruning-Richardson, C. Hogg, , L. F. Stead

This study identifies two IDHwt glioblastoma subtypes based on transcriptional response to treatment, with distinct resistance mechanisms and potential therapeutic implications.

bioRxiv · Feb 3, 2023Cancer Biology

JARID2 facilitates transcriptional reprogramming in glioblastoma in response to standard treatment

N. Rippaus, A. F-Bruns, G. Tanner, C. Taylor, A. Droop, A. Bruning-Richardson, M. A. Care, J. Wilkinson, M. D. Jenkinson, A. Brodbelt, A. Chakrabarty, A. Ismail, S. C. Short, L. F. Stead

The paper identifies JARID2-mediated transcriptional reprogramming in glioblastoma post-treatment, showing dysregulated genes with JARID2 binding sites are universally altered in recurrent tumors.

bioRxiv · Jun 17, 2019 · PreprintCancer Biology